Martin R. Pollak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martin R. Pollak has a total of 332 co-authors. Here are the top co-authors by number of shared publications:
- David J. Friedman
Renal Division, Beth Israel Deaconess Medical Center, Boston, USA
22 shared publications Giulio Genovese
Stanley Center for Psychiatric Research, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts
10 shared publicationsSeth L. Alper
Harvard
7 shared publications- Johannes Schlondorff
Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
6 shared publications Balajikarthick Subramanian
Nephrology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215
5 shared publications- Balajikarthick Subramanian
Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
5 shared publications
Latest Publications
- 8 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (11) , 2421-2434
Purine Metabolism Regulates the Severity of APOL1 Nephropathy
Key Points: Apolipoprotein L1 risk variants altered purine metabolic pathways. 5-aminoimidazole-4-carboxamide riboside supplementation alleviated apolipoprotein L1 risk variant–induced cytotoxicity. Background: Thirteen percent of African American people have a high-risk apolipoprotein L1 ( APOL1) genotype, carrying two risk alleles (G1/G1, G1/G2, or G2/G2). The mechanisms underlying nephropathy caused by these APOL1 risk variant genotypes are not fully understood. Downstream of gene function, homeostatic maintenance of a complex and interconnected network of metabolites is essential for normal kidney function. However, this metabolic network can be rerouted by genetic changes or environmental insults, both of which can contribute to the development and/or progression of kidney diseases. APOL1 nephropathy exhibits both genetic and environmental triggers, but how APOL1 might alter metabolic homeostasis and how such changes may contribute to disease progression remains unclear. Methods: APOL1 nephropathy was induced in human bacterial artificial chromosome transgenic APOL1 mice by IFN- γ adenovirus. Nontargeted metabolomics was performed on glomeruli from risk variant (G1/G1 and G2/G2) and nonrisk variant (G0/G0) mice as well as on tetracycline-inducible cell lines expressing risk or nonrisk variants. Metabolic signaling pathways in risk or nonrisk groups were compared, and transcriptional changes driving these metabolic differences were identified. Metabolic interventions were performed in both APOL1 risk and nonrisk variant–expressing cells and in mice. The effect of metabolic intervention was evaluated by cytotoxicity assays and urine albumin-to-creatinine ratios for cellular and in vivo responses, respectively. Results: Perturbed purine metabolism was the strongest metabolite differentiator between high-risk and low-risk APOL1 genotypes in cultured cells and in whole glomeruli. Expression of APOL1 G2/G2 downregulated the rate-limiting enzymes of purine biosynthesis and induced ATP depletion. In APOL1 G2/G2-expressing cells, supplementation with the purine biosynthesis precursor 5-aminoimidazole-4-carboxamide riboside (AICAr) rescued purine biosynthesis, reduced cytotoxicity, and boosted ATP. In IFN- γ treated APOL1 G2/G2 transgenic mice, AICAr administration boosted purine biosynthesis, decreased kidney phosphorylated AMP-activated protein kinase, and reduced albuminuria levels. AICAr treatment rescued G2 mouse podocyte death induced by the inflammatory stimuli of combined IFN- γ and toll-like receptor 1/2 agonist. Conclusions: Increasing purine biosynthesis mitigated APOL1 risk variant–induced injury in cell and transgenic mouse models of APOL1 kidney disease.
- 8 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (11) , 2421-2434
Purine Metabolism Regulates the Severity of APOL1 Nephropathy
Key Points: Apolipoprotein L1 risk variants altered purine metabolic pathways. 5-aminoimidazole-4-carboxamide riboside supplementation alleviated apolipoprotein L1 risk variant–induced cytotoxicity. Background: Thirteen percent of African American people have a high-risk apolipoprotein L1 ( APOL1) genotype, carrying two risk alleles (G1/G1, G1/G2, or G2/G2). The mechanisms underlying nephropathy caused by these APOL1 risk variant genotypes are not fully understood. Downstream of gene function, homeostatic maintenance of a complex and interconnected network of metabolites is essential for normal kidney function. However, this metabolic network can be rerouted by genetic changes or environmental insults, both of which can contribute to the development and/or progression of kidney diseases. APOL1 nephropathy exhibits both genetic and environmental triggers, but how APOL1 might alter metabolic homeostasis and how such changes may contribute to disease progression remains unclear. Methods: APOL1 nephropathy was induced in human bacterial artificial chromosome transgenic APOL1 mice by IFN- γ adenovirus. Nontargeted metabolomics was performed on glomeruli from risk variant (G1/G1 and G2/G2) and nonrisk variant (G0/G0) mice as well as on tetracycline-inducible cell lines expressing risk or nonrisk variants. Metabolic signaling pathways in risk or nonrisk groups were compared, and transcriptional changes driving these metabolic differences were identified. Metabolic interventions were performed in both APOL1 risk and nonrisk variant–expressing cells and in mice. The effect of metabolic intervention was evaluated by cytotoxicity assays and urine albumin-to-creatinine ratios for cellular and in vivo responses, respectively. Results: Perturbed purine metabolism was the strongest metabolite differentiator between high-risk and low-risk APOL1 genotypes in cultured cells and in whole glomeruli. Expression of APOL1 G2/G2 downregulated the rate-limiting enzymes of purine biosynthesis and induced ATP depletion. In APOL1 G2/G2-expressing cells, supplementation with the purine biosynthesis precursor 5-aminoimidazole-4-carboxamide riboside (AICAr) rescued purine biosynthesis, reduced cytotoxicity, and boosted ATP. In IFN- γ treated APOL1 G2/G2 transgenic mice, AICAr administration boosted purine biosynthesis, decreased kidney phosphorylated AMP-activated protein kinase, and reduced albuminuria levels. AICAr treatment rescued G2 mouse podocyte death induced by the inflammatory stimuli of combined IFN- γ and toll-like receptor 1/2 agonist. Conclusions: Increasing purine biosynthesis mitigated APOL1 risk variant–induced injury in cell and transgenic mouse models of APOL1 kidney disease.
- 21 February 2026
- Published by Elsevier in Seminars in Nephrology
- Vol. 46 (2-3) , 151684
Tension at the Barrier: Intraglomerular Pressure and the Podocyte Response
- 21 February 2026
- Published by Elsevier in Seminars in Nephrology
- Vol. 46 (2-3) , 151684
Tension at the Barrier: Intraglomerular Pressure and the Podocyte Response
- 28 October 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 700-712
Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection
Key Points: Testican-2 reduced adriamycin-induced podocyte injury in vitro and in vivo . Testican-2 interacted with vitronectin and reduced vitronectin-mediated integrin α V β 3 activation in vitro . Exogenous testican-2 circulated to the kidney, bound vitronectin, and conferred podocyte protection, even when endogenous testican-2 was absent. Background: Testican-2 is a podocyte-derived glycoprotein encoded by SPOCK2 . Circulating levels of testican-2 are associated with less glomerulosclerosis and better kidney prognosis, but its biologic function in the podocyte is unknown. Methods: We studied the protective effect of testican-2 on immortalized cultured human podocytes and in mice treated with adriamycin. We used immunoprecipitation mass spectrometry to identify binding partners of testican-2 and biolayer interferometry to characterize these protein–protein interactions. Using global and podocyte-specific Spock2 knockout mice, we assessed the effect of testican-2 deficiency in models of podocyte injury and also tested whether exogenous testican-2 confers podocyte protection in testican-2–deficient mice. Finally, we analyzed testican-2 expression in human kidney biopsy samples. Results: Testican-2 reduced adriamycin-induced podocyte injury in cultured human podocytes and mice. Vitronectin was a strong binding partner for testican-2, and testican-2 inhibited the interaction between vitronectin and integrin α V β 3, an effector of podocyte injury. Consistent with this, testican-2 administration reduced activation of integrin β 3 in injured podocytes. Furthermore, Spock2 deficiency increased susceptibility to podocyte injury due to adriamycin- and streptozotocin-induced diabetes, as determined by albuminuria, foot process effacement, nephrin expression, and Wilms' tumor 1-positive podocyte number. Importantly, exogenous testican-2 circulated to the kidney, bound to vitronectin, reduced vitronectin-integrin β 3 interaction, and reduced podocyte injury in Spock2 -deficient mice. Finally, glomerular testican-2 expression was reduced in human focal segmental glomerulosclerosis and diabetic kidney disease, but not tubulointerstitial nephropathy. Conclusions: Testican-2 modulated the podocyte's interaction with its extracellular matrix and had a functional role in kidney protection.
- 28 October 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 700-712
Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection
Key Points: Testican-2 reduced adriamycin-induced podocyte injury in vitro and in vivo . Testican-2 interacted with vitronectin and reduced vitronectin-mediated integrin α V β 3 activation in vitro . Exogenous testican-2 circulated to the kidney, bound vitronectin, and conferred podocyte protection, even when endogenous testican-2 was absent. Background: Testican-2 is a podocyte-derived glycoprotein encoded by SPOCK2 . Circulating levels of testican-2 are associated with less glomerulosclerosis and better kidney prognosis, but its biologic function in the podocyte is unknown. Methods: We studied the protective effect of testican-2 on immortalized cultured human podocytes and in mice treated with adriamycin. We used immunoprecipitation mass spectrometry to identify binding partners of testican-2 and biolayer interferometry to characterize these protein–protein interactions. Using global and podocyte-specific Spock2 knockout mice, we assessed the effect of testican-2 deficiency in models of podocyte injury and also tested whether exogenous testican-2 confers podocyte protection in testican-2–deficient mice. Finally, we analyzed testican-2 expression in human kidney biopsy samples. Results: Testican-2 reduced adriamycin-induced podocyte injury in cultured human podocytes and mice. Vitronectin was a strong binding partner for testican-2, and testican-2 inhibited the interaction between vitronectin and integrin α V β 3, an effector of podocyte injury. Consistent with this, testican-2 administration reduced activation of integrin β 3 in injured podocytes. Furthermore, Spock2 deficiency increased susceptibility to podocyte injury due to adriamycin- and streptozotocin-induced diabetes, as determined by albuminuria, foot process effacement, nephrin expression, and Wilms' tumor 1-positive podocyte number. Importantly, exogenous testican-2 circulated to the kidney, bound to vitronectin, reduced vitronectin-integrin β 3 interaction, and reduced podocyte injury in Spock2 -deficient mice. Finally, glomerular testican-2 expression was reduced in human focal segmental glomerulosclerosis and diabetic kidney disease, but not tubulointerstitial nephropathy. Conclusions: Testican-2 modulated the podocyte's interaction with its extracellular matrix and had a functional role in kidney protection.
- 6 March 2025
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 34 (3) , 191-198
APOL1-associated kidney disease: modulators of the genotype-phenotype relationship
Purpose of review: Apolipoprotein-L1 (APOL1) G1 and G2 risk variants, found in people of recent west sub-Saharan African ancestry, dramatically increase the likelihood of kidney disease, yet the incomplete penetrance an diverse clinical manifestations underscore the need to understand the molecular and environmental factors that modulate APOL1-mediated toxicity. Recent findings: Recent studies confirm that risk variants exert a toxic gain-of-function effect, exacerbated by inflammatory triggers such as HIV infection and COVID-19. Epigenetic mechanisms and microRNA pathways further modulate APOL1 expression, influencing disease penetrance. Multiple models have clarified how subcellular localization, signal peptide processing, and interactions with the endoplasmic reticulum may contribute to pathogenesis. Therapeutic advances include inhibitors targeting APOL1 ion channel activity and strategies that block key inflammatory signaling pathways. Summary: These findings highlight a multifaceted disease process driven by both the intrinsic toxic potential of APOL1 variants and numerous extrinsic triggers. Understanding this complex interplay will be pivotal for risk stratification and the development of precision therapies, potentially improving outcomes for populations disproportionately affected by APOL1-associated kidney disease.
- 6 March 2025
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 34 (3) , 191-198
APOL1-associated kidney disease: modulators of the genotype-phenotype relationship
Purpose of review: Apolipoprotein-L1 (APOL1) G1 and G2 risk variants, found in people of recent west sub-Saharan African ancestry, dramatically increase the likelihood of kidney disease, yet the incomplete penetrance an diverse clinical manifestations underscore the need to understand the molecular and environmental factors that modulate APOL1-mediated toxicity. Recent findings: Recent studies confirm that risk variants exert a toxic gain-of-function effect, exacerbated by inflammatory triggers such as HIV infection and COVID-19. Epigenetic mechanisms and microRNA pathways further modulate APOL1 expression, influencing disease penetrance. Multiple models have clarified how subcellular localization, signal peptide processing, and interactions with the endoplasmic reticulum may contribute to pathogenesis. Therapeutic advances include inhibitors targeting APOL1 ion channel activity and strategies that block key inflammatory signaling pathways. Summary: These findings highlight a multifaceted disease process driven by both the intrinsic toxic potential of APOL1 variants and numerous extrinsic triggers. Understanding this complex interplay will be pivotal for risk stratification and the development of precision therapies, potentially improving outcomes for populations disproportionately affected by APOL1-associated kidney disease.
- 1 January 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (1)
Cover Image
- Open Access
- 10 December 2024
- Published by Oxford University Press (OUP) in G3: Genes, Genomes, Genetics
- Vol. 15 (2)
The APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination event
Black Americans are 3–4 times more likely to develop nondiabetic kidney disease than other populations. Exclusively found in people of recent African (AFR) ancestry, risk variants in Apolipoprotein L1 (APOL1) termed G1 and G2 contribute significantly to this increased susceptibility. Our group and others showed that a missense variant in APOL1, rs73885316 (p.N264K, “M1”), is remarkably protective against APOL1 kidney disease when co-inherited with the G2 risk allele. Since the distance between the M1 and G2 variants is only 367 base pairs, we initially suspected that 2 independent mutation events occurred to create non-risk M1-G0 and M1-G2 haplotypes. Here, we examined APOL1 haplotypes in individuals of AFR ancestry from the 1000 Genomes Project, the Nephrotic Syndrome Study Network (NEPTUNE), and an ancient individual from the Allen Ancient Genome Diversity Project to determine how the M1-G2 haplotype arose. We demonstrate that M1 most likely first appeared on a non-risk G0 haplotype, and that a subsequent recombination event bypassed strong recombination hotspots flanking APOL1 and occurred between p.N388Y389del on a G2 haplotype and M1 on a G0 haplotype to create the M1-G2 haplotype. Observing a recombination event within a small region between clinically relevant loci emphasizes the importance of studying the entire haplotype repertoire of a disease gene and the impact of haplotype backgrounds in disease susceptibility.
- 10 December 2024
- Published by Oxford University Press (OUP) in G3: Genes, Genomes, Genetics
- Vol. 15 (2)
Open AccessThe APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination event
Black Americans are 3–4 times more likely to develop nondiabetic kidney disease than other populations. Exclusively found in people of recent African (AFR) ancestry, risk variants in Apolipoprotein L1 (APOL1) termed G1 and G2 contribute significantly to this increased susceptibility. Our group and others showed that a missense variant in APOL1, rs73885316 (p.N264K, “M1”), is remarkably protective against APOL1 kidney disease when co-inherited with the G2 risk allele. Since the distance between the M1 and G2 variants is only 367 base pairs, we initially suspected that 2 independent mutation events occurred to create non-risk M1-G0 and M1-G2 haplotypes. Here, we examined APOL1 haplotypes in individuals of AFR ancestry from the 1000 Genomes Project, the Nephrotic Syndrome Study Network (NEPTUNE), and an ancient individual from the Allen Ancient Genome Diversity Project to determine how the M1-G2 haplotype arose. We demonstrate that M1 most likely first appeared on a non-risk G0 haplotype, and that a subsequent recombination event bypassed strong recombination hotspots flanking APOL1 and occurred between p.N388Y389del on a G2 haplotype and M1 on a G0 haplotype to create the M1-G2 haplotype. Observing a recombination event within a small region between clinically relevant loci emphasizes the importance of studying the entire haplotype repertoire of a disease gene and the impact of haplotype backgrounds in disease susceptibility.
- Open Access
- 2 December 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (1) , 38-48
Dynll1-PI31 Interaction Enhances Proteolysis Through the Proteasome, Representing a Novel Therapeutic Target for INF2-Related FSGS
Key Points: The R218Q mutation disrupts sequestration of Dynll1 by inverted formin 2, promotes Dynll1-PI31 interaction, and enhances proteasome-mediated nephrin degradation. Suppression of proteasome-mediated proteolysis with proteasome inhibitors is a new therapeutic strategy for inverted formin 2-mediated FSGS. Background: The p.Arg218Gln (R218Q) mutation in the inverted formin 2 (INF2) gene causes podocytopathy prone to FSGS. This mutation disrupts the ability of INF2 to sequester dynein light chain 1 (DYNLL1), thus promoting dynein-mediated mistrafficking of the slit diaphragm protein, nephrin, to proteolytic pathways. Bortezomib, a proteasome inhibitor, stabilizes nephrin in R218Q knockin (KI) podocytes, suggesting a role for the ubiquitin proteasome system (UPS) in dynein-driven pathogenesis. However, the link between dynein and the UPS is unknown. This study tested the hypothesis that INF2 R218Q promotes proteasome-mediated degradation of nephrin through an increased interaction between Dynll1 and the proteasomal inhibitor of 31kD (PI31), a Dynll1 adaptor that potentially couples the UPS with dynein cargoes. Methods: The essential role of PI31 in UPS-mediated degradation of nephrin, a known dynein cargo, was studied in cultured R218Q KI mouse podocytes by applying genetic or chemical interventions to inhibit the activity of PI31 or of the proteasome. The protective effect of bortezomib in dynein-driven podocytopathy and FSGS was tested in R218Q KI mice challenged with puromycin aminonucleoside, a murine model of FSGS. Results: The R218Q mutation in INF2 disrupted sequestration of Dynll1 by INF2, allowing Dynll1 to be captured by PI31 and promoting dynein-mediated transport of nephrin to the proteasome. Each of the following manipulations was sufficient to restore nephrin proteostasis in R218Q KI podocytes: knocking down Dynll1 or PI31, inactivating dynein, or inhibiting the activity of the proteasome. In R218Q KI mice challenged with puromycin aminonucleoside, dynein-mediated mistrafficking and depletion of nephrin were correlated with increased Dynll1-PI31 interaction; the resulting podocytopathy and FSGS were ameliorated by bortezomib. Conclusions: The Dynll1-PI31 interaction facilitates dynein-driven trafficking of nephrin to the proteasome and proteasome-mediated degradation of nephrin in INF2-R218Q-mediated podocytopathy. This mechanism offers new therapeutic strategies for INF2-related FSGS by using pharmacologically available proteasome inhibitors.
- 2 December 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (1) , 38-48
Open AccessDynll1-PI31 Interaction Enhances Proteolysis Through the Proteasome, Representing a Novel Therapeutic Target for INF2-Related FSGS
Key Points: The R218Q mutation disrupts sequestration of Dynll1 by inverted formin 2, promotes Dynll1-PI31 interaction, and enhances proteasome-mediated nephrin degradation. Suppression of proteasome-mediated proteolysis with proteasome inhibitors is a new therapeutic strategy for inverted formin 2-mediated FSGS. Background: The p.Arg218Gln (R218Q) mutation in the inverted formin 2 (INF2) gene causes podocytopathy prone to FSGS. This mutation disrupts the ability of INF2 to sequester dynein light chain 1 (DYNLL1), thus promoting dynein-mediated mistrafficking of the slit diaphragm protein, nephrin, to proteolytic pathways. Bortezomib, a proteasome inhibitor, stabilizes nephrin in R218Q knockin (KI) podocytes, suggesting a role for the ubiquitin proteasome system (UPS) in dynein-driven pathogenesis. However, the link between dynein and the UPS is unknown. This study tested the hypothesis that INF2 R218Q promotes proteasome-mediated degradation of nephrin through an increased interaction between Dynll1 and the proteasomal inhibitor of 31kD (PI31), a Dynll1 adaptor that potentially couples the UPS with dynein cargoes. Methods: The essential role of PI31 in UPS-mediated degradation of nephrin, a known dynein cargo, was studied in cultured R218Q KI mouse podocytes by applying genetic or chemical interventions to inhibit the activity of PI31 or of the proteasome. The protective effect of bortezomib in dynein-driven podocytopathy and FSGS was tested in R218Q KI mice challenged with puromycin aminonucleoside, a murine model of FSGS. Results: The R218Q mutation in INF2 disrupted sequestration of Dynll1 by INF2, allowing Dynll1 to be captured by PI31 and promoting dynein-mediated transport of nephrin to the proteasome. Each of the following manipulations was sufficient to restore nephrin proteostasis in R218Q KI podocytes: knocking down Dynll1 or PI31, inactivating dynein, or inhibiting the activity of the proteasome. In R218Q KI mice challenged with puromycin aminonucleoside, dynein-mediated mistrafficking and depletion of nephrin were correlated with increased Dynll1-PI31 interaction; the resulting podocytopathy and FSGS were ameliorated by bortezomib. Conclusions: The Dynll1-PI31 interaction facilitates dynein-driven trafficking of nephrin to the proteasome and proteasome-mediated degradation of nephrin in INF2-R218Q-mediated podocytopathy. This mechanism offers new therapeutic strategies for INF2-related FSGS by using pharmacologically available proteasome inhibitors.
- Open Access
- 15 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (46) , eadr1017
INF2 mutations cause kidney disease through a gain-of-function mechanism
Heterozygosity for inverted formin-2 (INF2) mutations causes focal segmental glomerulosclerosis (FSGS) with or without Charcot-Marie-Tooth disease. A key question is whether the disease is caused by gain-of-function effects on INF2 or loss of function (haploinsufficiency). Despite established roles in multiple cellular processes, neither INF2 knockout mice nor mice with a disease-associated point mutation display an evident kidney or neurologic phenotype. Here, we compared responses to puromycin aminonucleoside (PAN)–induced kidney injury between INF2 R218Q and INF2 knockout mice. R218Q INF2 mice are susceptible to glomerular disease, in contrast to INF2 knockout mice. Colocalization, coimmunoprecipitation analyses, and cellular actin measurements showed that INF2 R218Q confers a gain-of-function effect on the actin cytoskeleton. RNA expression analysis showed that adhesion and mitochondria-related pathways were enriched in the PAN-treated R218Q mice. Both podocytes from INF2 R218Q mice and human kidney organoids with an INF2 mutation (S186P) recapitulate adhesion and mitochondrial phenotypes. Thus, gain-of-function mechanisms drive INF2-related FSGS and explain this disease’s autosomal dominant inheritance.
- 15 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (46) , eadr1017
Open AccessINF2 mutations cause kidney disease through a gain-of-function mechanism
Heterozygosity for inverted formin-2 (INF2) mutations causes focal segmental glomerulosclerosis (FSGS) with or without Charcot-Marie-Tooth disease. A key question is whether the disease is caused by gain-of-function effects on INF2 or loss of function (haploinsufficiency). Despite established roles in multiple cellular processes, neither INF2 knockout mice nor mice with a disease-associated point mutation display an evident kidney or neurologic phenotype. Here, we compared responses to puromycin aminonucleoside (PAN)–induced kidney injury between INF2 R218Q and INF2 knockout mice. R218Q INF2 mice are susceptible to glomerular disease, in contrast to INF2 knockout mice. Colocalization, coimmunoprecipitation analyses, and cellular actin measurements showed that INF2 R218Q confers a gain-of-function effect on the actin cytoskeleton. RNA expression analysis showed that adhesion and mitochondria-related pathways were enriched in the PAN-treated R218Q mice. Both podocytes from INF2 R218Q mice and human kidney organoids with an INF2 mutation (S186P) recapitulate adhesion and mitochondrial phenotypes. Thus, gain-of-function mechanisms drive INF2-related FSGS and explain this disease’s autosomal dominant inheritance.
- Open Access
Missense Mutant Gain-of-Function Causes Inverted Formin 2 (INF2)-Related Focal Segmental Glomerulosclerosis (FSGS)
Inverted formin-2 (INF2) gene mutations are among the most common causes of genetic focal segmental glomerulosclerosis (FSGS) with or without Charcot-Marie-Tooth (CMT) disease. Recent studies suggest that INF2, through its effects on actin and microtubule arrangement, can regulate processes including vesicle trafficking, cell adhesion, mitochondrial calcium uptake, mitochondrial fission, and T-cell polarization. Despite roles for INF2 in multiple cellular processes, neither the human pathogenic R218Q INF2 point mutation nor the INF2 knock-out allele is sufficient to cause disease in mice. This discrepancy challenges our efforts to explain the disease mechanism, as the link between INF2-related processes, podocyte structure, disease inheritance pattern, and their clinical presentation remains enigmatic. Here, we compared the kidney responses to puromycin aminonucleoside (PAN) induced injury between R218Q INF2 point mutant knock-in and INF2 knock-out mouse models and show that R218Q INF2 mice are susceptible to developing proteinuria and FSGS. This contrasts with INF2 knock-out mice, which show only a minimal kidney phenotype. Co-localization and co-immunoprecipitation analysis of wild-type and mutant INF2 coupled with measurements of cellular actin content revealed that the R218Q INF2 point mutation confers a gain-of-function effect by altering the actin cytoskeleton, facilitated in part by alterations in INF2 localization. Differential analysis of RNA expression in PAN-stressed heterozygous R218Q INF2 point-mutant and heterozygous INF2 knock-out mouse glomeruli showed that the adhesion and mitochondria-related pathways were significantly enriched in the disease condition. Mouse podocytes with R218Q INF2, and an INF2-mutant human patient’s kidney organoid-derived podocytes with an S186P INF2 mutation, recapitulate the defective adhesion and mitochondria phenotypes. These results link INF2-regulated cellular processes to the onset and progression of glomerular disease. Thus, our data demonstrate that gain-of-function mechanisms drive INF2-related FSGS and explain the autosomal dominant inheritance pattern of this disease.
Open AccessMissense Mutant Gain-of-Function Causes Inverted Formin 2 (INF2)-Related Focal Segmental Glomerulosclerosis (FSGS)
Inverted formin-2 (INF2) gene mutations are among the most common causes of genetic focal segmental glomerulosclerosis (FSGS) with or without Charcot-Marie-Tooth (CMT) disease. Recent studies suggest that INF2, through its effects on actin and microtubule arrangement, can regulate processes including vesicle trafficking, cell adhesion, mitochondrial calcium uptake, mitochondrial fission, and T-cell polarization. Despite roles for INF2 in multiple cellular processes, neither the human pathogenic R218Q INF2 point mutation nor the INF2 knock-out allele is sufficient to cause disease in mice. This discrepancy challenges our efforts to explain the disease mechanism, as the link between INF2-related processes, podocyte structure, disease inheritance pattern, and their clinical presentation remains enigmatic. Here, we compared the kidney responses to puromycin aminonucleoside (PAN) induced injury between R218Q INF2 point mutant knock-in and INF2 knock-out mouse models and show that R218Q INF2 mice are susceptible to developing proteinuria and FSGS. This contrasts with INF2 knock-out mice, which show only a minimal kidney phenotype. Co-localization and co-immunoprecipitation analysis of wild-type and mutant INF2 coupled with measurements of cellular actin content revealed that the R218Q INF2 point mutation confers a gain-of-function effect by altering the actin cytoskeleton, facilitated in part by alterations in INF2 localization. Differential analysis of RNA expression in PAN-stressed heterozygous R218Q INF2 point-mutant and heterozygous INF2 knock-out mouse glomeruli showed that the adhesion and mitochondria-related pathways were significantly enriched in the disease condition. Mouse podocytes with R218Q INF2, and an INF2-mutant human patient’s kidney organoid-derived podocytes with an S186P INF2 mutation, recapitulate the defective adhesion and mitochondria phenotypes. These results link INF2-regulated cellular processes to the onset and progression of glomerular disease. Thus, our data demonstrate that gain-of-function mechanisms drive INF2-related FSGS and explain the autosomal dominant inheritance pattern of this disease.
- Open Access
- 20 February 2024
- Published by S. Karger AG in Glomerular Diseases
- Vol. 4 (1) , 43-48
APOL1 genotyping is incomplete without testing for the protective M1 modifier p.N264K variant
Box 1Clinical implications of APOL1 p.N264K as genetic modifier of APOL1 G2-mediated kidney diseaseFive different haplotypes for APOL1 risk and modifier variants (G0, G0-M1, G1, G2, G2-M1)G2-M1 genotypes should be reclassified as non-HR genotypeKidneys from G2-M1 donors are at low risk of APOL1-mediated kidney diseaseM1 p.N264K provides a new target for novel therapy of APOL1-mediated kidney diseasesPrecise design of clinical trials for APOL1-mediated kidney disease based on haplotype risks
- 20 February 2024
- Published by S. Karger AG in Glomerular Diseases
- Vol. 4 (1) , 43-48
Open AccessAPOL1 genotyping is incomplete without testing for the protective M1 modifier p.N264K variant
Box 1Clinical implications of APOL1 p.N264K as genetic modifier of APOL1 G2-mediated kidney diseaseFive different haplotypes for APOL1 risk and modifier variants (G0, G0-M1, G1, G2, G2-M1)G2-M1 genotypes should be reclassified as non-HR genotypeKidneys from G2-M1 donors are at low risk of APOL1-mediated kidney diseaseM1 p.N264K provides a new target for novel therapy of APOL1-mediated kidney diseasesPrecise design of clinical trials for APOL1-mediated kidney disease based on haplotype risks